Form 4: ALX Oncology Chief Medical Officer Alan Sandler Granted Stock Options
SEC Form 4 Filing
Alan Sandler, Chief Medical Officer of ALX Oncology Holdings Inc., was granted 100,000 stock options on January 21, 2025, according to a recent SEC filing.
Summary
- Alan Sandler, the Chief Medical Officer of ALX Oncology Holdings Inc., was granted 100,000 employee stock options.
- The options were granted on January 21, 2025, with an exercise price of $1.65 per share.
- The options vest in 48 equal monthly installments starting on February 21, 2025.
- The options expire on January 20, 2035.
- A power of attorney was executed on January 22, 2025, authorizing certain individuals to file SEC forms on behalf of Alan Sandler.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.
Positives
- The grant of stock options aligns the interests of the Chief Medical Officer with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard practice in the biotech industry for executive compensation.
- The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
- The exercise price of $1.65 is a common practice, often set at or near the market price at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of the stock option grant. |
| 01/22/2025 | Date of execution of the power of attorney. |
| 01/23/2025 | Date of the SEC filing. |
| 02/21/2025 | Start date for monthly vesting of the stock options. |
| 01/20/2035 | Expiration date of the stock options. |
Keywords
stock options, insider trading, executive compensation, ALX Oncology, ALXO, SEC Form 4, Alan Sandler, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.